<table><tr><td>Product name 
(reference drugs/targets)</td><td>Indications</td><td>Progress as at the Latest 
Practicable Date</td></tr><tr><td colspan="3">Smooth progress of domestic clinical projects</td></tr><tr><td>HLX10+ HLX07</td><td>head and neck 
squamous cell 
carcinoma (HNSCC)</td><td>In July 2020, the first patient dosing 
was comlpeted in a hipase 2 clincal trial 
in mainland China</td></tr><tr><td>HLX10+ HLX04</td><td>Solid tumor</td><td>In September 2020, the enrollment of 
subjects was comlpeted in a hpase 1 
clinical trial</td></tr><tr><td>HLX10+ HLX04</td><td>Hepatocellular 
Carcinoma (HCC)</td><td>In January 2021, the enrollment of 
subjects was comlpeted in a hpase 2 
clinical trial</td></tr><tr><td>HLX10+HLX04</td><td>Metastatic colorectal 
cancer (mCRC)</td><td>In March 2021, the first patient dosing 
was comlpeted in a Phase 2/3 clinical 
trial in mainland China</td></tr><tr><td>HLX55 (innovative anti-c-Met 
 monoclonal antibody)</td><td>Solid tumor</td><td>In March 2020, the first patient dosing 
was comlpeted in a hilpase 1 clinca trial 
in Taiwan, China</td></tr><tr><td>HLX07 (modified innovative 
 anti-EGFR monoclonal 
 antibody)</td><td>Solid tumor</td><td>In March 2020, the relevant clinical 
research report was comlpeted for the 
h1ilpase  clinical tra</td></tr><tr><td>HLX11 (pertuzumab)</td><td>Breast cancer (BC)</td><td>In September 2020, the first patient 
dosing was comlpeted in a hpase 1 
clinical trial in mainland China</td></tr><tr><td>HLX14 (desumumab)</td><td>Osteoporosis (OP)</td><td>In November 2020, the first patient 
dosinlg was competed in a hpase 1 
clinical trial in mainland China</td></tr></table>

<table><tr><td>Product name 
(reference drugs/targets)</td><td>Indications</td><td>Progress as at the Latest 
Practicable Date</td></tr><tr><td colspan="3">Efficient advancement on IND aliippcaton for pre-clinical development projects</td></tr><tr><td>HLX13 (iilipmumab)</td><td>Melanoma, Renal Cell 
Carcinoma (RCC), 
Metastatic Colorectal 
Cancer (mCRC)</td><td>In January 2020, the investigational new 
drug alipcatipon (IND) was accepted by 
the NMPA
In April 2020, the investigational new 
drug alippcation (IND) was approved by 
the NMPA</td></tr><tr><td>HLX56 (anti-DR4 monoclonal 
 antibody)</td><td>Solid tumor</td><td>In May 2020, the investigational new 
drulg aippcation ( IND) was approved 
by the Ministry of Health and Welfare 
of Taiwan.</td></tr><tr><td>HLX70 (anti-S1 fully human
 monoclonal 
 neutralizing antibody)</td><td>COVID-19</td><td>In October 2020, the investigational 
new druiNDg alppcation (I) was 
approved by the U.S. Food and Drug 
Administration (FDA)</td></tr><tr><td>HLX71 (ACE2-Fc receptor 
 fusion protein)</td><td>COVID-19</td><td>In November 2020, the investigational 
new druiNg alppcation (ID) was 
approved by the U.S. Food and Drug 
Administration (FDA)</td></tr><tr><td>HLX15 (daratumumab)</td><td>Multillpe myeoma 
(MM)</td><td>In November 2020, the investigational 
new drulg aippcation (IND) was 
accepted by the NMPA
In January 2021, the investigational new 
drug alippcation (IND) was approved by 
the NMPA</td></tr><tr><td>HLX26 (Recombinant anti-
 LAG-3 human 
 monoclonal antibody 
 injection)</td><td>Solid tumor, lymhpoma</td><td>In January 2021, the investigational new 
drug alippcation (IND) was accepted by 
the NMPA</td></tr></table>